U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H29N.H3NO3S
Molecular Weight 296.47
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OCTAMYLAMINE SULFAMATE

SMILES

NS(O)(=O)=O.CC(C)CCCC(C)NCCC(C)C

InChI

InChIKey=FDRZMEIDDOWJER-UHFFFAOYSA-N
InChI=1S/C13H29N.H3NO3S/c1-11(2)7-6-8-13(5)14-10-9-12(3)4;1-5(2,3)4/h11-14H,6-10H2,1-5H3;(H3,1,2,3,4)

HIDE SMILES / InChI
Molecular Formula C13H29N
Molecular Weight 199.3761
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula H3NO3S
Molecular Weight 97.094
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Octamylamine is an Antispasmodic. Trademark: Octinum D.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Octinum-D

Approved Use

Antispasmodic; for digestive, urinary tract and sphincter cramps, migraine headaches, urinary tract and hiccup, gastrointestinal tract equipment examination. For canker, cholecystitis, cholelithiasis diseases caused by abdominal pain, and the effect of atropine similar, but no other adverse reactions, dry mouth.
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C19
2057
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2C19
2141
 no
CYP2C9
2497
 no
CYP3A4
2633
 no
CYP2D6
2546
 yes [IC50 0.5495 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
[Octin, hydro-octin, octin D; a contribution to the analysis of their mechanism of action].
1955
[Pylorus hypertrophy in adults, x-rayed while under effect of octin D].
1953
[Octinum D in the development of synthetic spasmolytics].
1952-04
Patents

Patents

CA2526616C
4
US20150374826
4
US8591941
6

Sample Use Guides

In Vivo Use Guide
Oral: Each compound drops 25 to 40 drops
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:55:41 GMT 2025
Edited
by admin
on Mon Mar 31 21:55:41 GMT 2025
Record UNII
778333NHPO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OCTAMYLAMINE SULFAMIC ACID
Preferred Name English
OCTAMYLAMINE SULFAMATE
Common Name English
SULFAMIC ACID, COMPD. WITH 6-METHYL-N-(3-METHYLBUTYL)-2-HEPTANAMINE (1:1)
Systematic Name English
SULFAMIC ACID, COMPD. WITH N-ISOPENTYL-1,5-DIMETHYLHEXYLAMINE
Systematic Name English
Code System Code Type Description
CAS
96296-56-9
Created by admin on Mon Mar 31 21:55:41 GMT 2025 , Edited by admin on Mon Mar 31 21:55:41 GMT 2025
PRIMARY
FDA UNII
778333NHPO
Created by admin on Mon Mar 31 21:55:41 GMT 2025 , Edited by admin on Mon Mar 31 21:55:41 GMT 2025
PRIMARY
PUBCHEM
133065432
Created by admin on Mon Mar 31 21:55:41 GMT 2025 , Edited by admin on Mon Mar 31 21:55:41 GMT 2025
PRIMARY
Related Record Type Details
Structure of OCTAMYLAMINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966